NorthWest Biotherapeutics Inc (NWBO)

[Doktornolittle]

"And I do believe for a hold this long, some step in approval must be being discussed."

If there is/was an efficacy read for DCVax-L, and a request for consideration of some kind of approval, then I think the regulators would want to look at the efficacy of all other GBM therapies possible before they decide. Especially with subgroup issues becoming a focus for some therapies.

There was the Celldex Ph 3 trial some time ago to look at, then two Phase 2 unblindings for presentation at ASCO (one may have been open label, but still data compilation and presentation) and as you guys are pointing out, very recently the look at ARGS phase 3 50% interim data. Since the ARGS data is very recent... I think some reason to believe that there is a chance that this was the last of the data to be considered before making a decision on this alleged approval for DCVax-L.